Comprehensive Analysis of the Prognostic Significance of the TRIM Family in the Context of TP53 Mutations in Cancers

被引:2
|
作者
Vu, Trung [1 ]
Fowler, Annaliese [2 ]
McCarty, Nami [2 ]
机构
[1] Univ Texas Hlth Sci Ctr Houston, Brown Fdn Inst Mol Med Prevent Human Dis IMM, Ctr Stem Cell & Regenerat Dis, Houston, TX 77030 USA
[2] Texas A&M Univ, Dept Biomed Engn, Houston, TX 77030 USA
关键词
TP53; liver cancer; TRIM family; cell cycle; HEPATOCELLULAR-CARCINOMA; CELL-PROLIFERATION; GENE-EXPRESSION; P53; MICRORNAS; SURVIVAL; PROMOTES; MIR-34A;
D O I
10.3390/cancers15153792
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary The p53 protein is an important tumor suppressor, and TP53 mutations are frequently low survival rates of cancer patients. Mutations in TP53 lead in loss of tumor suppressing functions which result in the development of tumors. Meanwhile, several tripartite motif (TRIM) proteins are known to regulate cell growth and cell cycle transition. However, the relationship between TRIM family genes and TP53 mutations in cancer remains unknown. In this study, we analyzed the links between TP53 mutations and TRIM family proteins and evaluated the role of TRIM family proteins in cancer patients with TP53 mutation. Our findings identified the TRIM family members that are highly expressed in TP53 mutant tumors and important for the cell growth in the context of TP53 mutations. The p53 protein is an important tumor suppressor, and TP53 mutations are frequently associated with poor prognosis in various cancers. Mutations in TP53 result in a loss of p53 function and enhanced expression of cell cycle genes, contributing to the development and progression of cancer. Meanwhile, several tripartite motif (TRIM) proteins are known to regulate cell growth and cell cycle transition. However, the prognostic values between TP53 and TRIM family genes in cancer are unknown. In this study, we analyzed the relationship between the TP53 mutations and TRIM family proteins and evaluated the prognostic significance of TRIM family proteins in cancer patients with P53 mutations. Our findings identified specific TRIM family members that are upregulated in TP53 mutant tumors and are associated with the activation of genes related to a cell-cycle progression in the context of TP53 mutations.
引用
收藏
页数:16
相关论文
共 50 条
  • [41] PROGNOSTIC-SIGNIFICANCE OF TP53 ALTERATIONS IN BREAST-CARCINOMA
    ANDERSEN, TI
    HOLM, R
    NESLAND, JM
    HEIMDAL, KR
    OTTESTAD, L
    BORRESEN, AL
    BRITISH JOURNAL OF CANCER, 1993, 68 (03) : 540 - 548
  • [42] TP53 Mutation and Its Prognostic Significance in Waldenstrom's Macroglobulinemia
    Poulain, Stephanie
    Roumier, Christophe
    Bertrand, Elisabeth
    Renneville, Aline
    Caillault-Venet, Aurelie
    Doye, Emmanuelle
    Geffroy, Sandrine
    Sebda, Sheherazade
    Nibourel, Olivier
    Nudel, Morgane
    Herbaux, Charles
    Renaud, Loic
    Tomowiak, Cecile
    Guidez, Stephanie
    Tricot, Sabine
    Roche-Lestienne, Catherine
    Quesnel, Bruno
    Preudhomme, Claude
    Leleu, Xavier
    CLINICAL CANCER RESEARCH, 2017, 23 (20) : 6325 - 6335
  • [43] Evaluation of prognostic significance of TP53 expression signature in breast cancer
    Ishioka, Chikashi
    Ishida, T.
    Moriya, T.
    Shibata, H.
    Sasano, H.
    Ohuchi, N.
    Takahashi, S.
    CLINICAL & EXPERIMENTAL METASTASIS, 2007, 24 (04) : 247 - 247
  • [44] Prognostic Significance of TP53 Mutation Class in Acute Myeloid Leukemia
    Nichols, Meredith
    Jambhekar, Ashwini
    Bell, Timothy
    Nakashima, Megan
    Lovitch, Scott
    LABORATORY INVESTIGATION, 2024, 104 (03) : S1460 - S1461
  • [45] Genomic Context and TP53 Allele Frequency Define Prognostic Subgroups and Response Outcomes in TP53 Mutated Myelodysplastic Syndromes
    Montalban-Bravo, Guillermo
    Kanagal-Shamanna, Rashmi
    Benton, Christopher B.
    Class, Caleb
    Chien, Kelly S.
    Sasaki, Koji
    Naqvi, Kiran
    Alvarado, Yesid
    Kadia, Tapan M.
    Ravandi, Farhad
    Cortes, Jorge E.
    Daver, Naval G.
    Takahashi, Koichi
    DiNardo, Courtney D.
    Jabbour, Elias
    Borthakur, Gautam M.
    Pemmaraju, Naveen
    Konopleva, Marina Y.
    Pierce, Sherry A.
    Bueso-Ramos, Carlos E.
    Andreeff, Michael
    Patel, Keyur P.
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2019, 134
  • [46] Histopathological features of breast cancers in women with germline TP53 mutations.
    Masciari, S.
    Kandel, M.
    Digianni, L.
    Dillon, D.
    Li, F.
    Garber, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 548S - 548S
  • [47] HUMAN PAPILLOMAVIRUS DNA AND TP53 MUTATIONS IN LUNG CANCERS FROM BUTCHERS
    ALGHAMDI, AA
    SANDERS, CM
    KEEFE, M
    COGGON, D
    MAITLAND, NJ
    BRITISH JOURNAL OF CANCER, 1995, 72 (02) : 293 - 297
  • [48] TP53 mutations and Arg72Pro polymorphism in breast cancers
    Denisov, Evgeniy V.
    Cherdyntseva, Nadejda V.
    Litvyakov, Nicolay V.
    Slonimskaya, Elena M.
    Malinovskaya, Elena A.
    Voevoda, Mikhail I.
    Belyavskaya, Valentina A.
    Stegniy, Vladimir N.
    CANCER GENETICS AND CYTOGENETICS, 2009, 192 (02) : 93 - 95
  • [49] Phenotypical mapping of TP53 unique missense mutations spectrum in human cancers
    Malhotra, Lakshay
    Singh, Alankrita
    Kaur, Punit
    Ethayathulla, Abdul S.
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2024,
  • [50] TP53 mutations in myelodysplastic syndrome
    Misawa, S
    Horiike, S
    LEUKEMIA & LYMPHOMA, 1996, 23 (5-6) : 417 - 422